Evidence-Based Treatment of Pseudomonas aeruginosa Infections: A Critical Reappraisal
Arta Karruli1,2, Christian Catalini3, Chiara D'Amore4
1Department of Precision Medicine, University of Campania 'Luigi Vanvitelli', 80138 Naples, Italy.
Abstract:
Multidrug-resistant (MDR)/extensively drug-resistant (XDR) Pseudomonas aeruginosa is emerging as a major threat related to adverse patient outcomes. The goal of this review is to describe evidence-based empiric and targeted treatment regimens that can be exploited when dealing with suspected or confirmed infections due to MDR/XDR P. aeruginosa. P. aeruginosa has inherent resistance to many drug classes, the capacity to form biofilms, and most importantly, the ability to quickly acquire resistance to ongoing treatments. Based on the presence of risk factors for MDR/XDR infections and local epidemiology, where large proportions of strains are resistant to classic beta-lactams, the recommended empirical treatment for suspected P. aeruginosa infections is based on ceftolozane-tazobactam or ceftazidime-avibactam. Where local epidemiology indicates low rates of MDR/XDR and there are no risk factors, a third or fourth generation cephalosporin can be used in the context of a "carbapenem-sparing" strategy. Whenever feasible, antibiotic de-escalation is recommended after antimicrobial susceptibility tests suggest that it is appropriate, and de-escalation is based on different resistance mechanisms. Cefiderocol and imipenem-cilastatin-relebactam withstand most resistance mechanisms and may remain active in cases with resistance to other new antibiotics. Confronting the growing threat of MDR/XDR P. aeruginosa, treatment choices should be wise, sparing newer antibiotics when dealing with a suspected/confirmed susceptible P. aeruginosa strain and choosing the right option for MDR/XDR P. aeruginosa based on specific types and resistance mechanisms.
Insights
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa infections require careful treatment. New antibiotics like ceftolozane-tazobactam and ceftazidime-avibactam are key for empirical therapy, with de-escalation strategies crucial for managing resistance.
Area of Science:
- Clinical Microbiology and Infectious Diseases
- Antimicrobial Resistance
- Pharmacology
Background:
- Multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Pseudomonas aeruginosa* pose significant threats, leading to adverse patient outcomes.
- *P. aeruginosa* exhibits inherent resistance, biofilm formation, and rapid acquisition of resistance, complicating treatment strategies.
- Understanding local epidemiology and patient risk factors is crucial for effective management of MDR/XDR *P. aeruginosa* infections.
Purpose of the Study:
- To review evidence-based empiric and targeted treatment regimens for suspected or confirmed MDR/XDR *P. aeruginosa* infections.
- To guide clinicians in selecting appropriate antimicrobial therapies based on resistance patterns and clinical context.
Main Methods:
- Literature review of current evidence on MDR/XDR *P. aeruginosa* treatment.
- Analysis of recommended empirical and targeted antibiotic strategies.
- Consideration of antibiotic de-escalation based on antimicrobial susceptibility testing (AST) and resistance mechanisms.
Main Results:
- Ceftolozane-tazobactam or ceftazidime-avibactam are recommended for empirical treatment of suspected MDR/XDR *P. aeruginosa* infections, especially with risk factors or high local resistance.
- Carbapenem-sparing strategies using third or fourth-generation cephalosporins may be appropriate in low-resistance settings without risk factors.
- Cefiderocol and imipenem-cilastatin-relebactam demonstrate activity against many resistant strains, offering options for difficult-to-treat infections.
Conclusions:
- Judicious antibiotic selection is paramount in combating MDR/XDR *P. aeruginosa*.
- Sparing newer agents for susceptible strains and tailoring therapy to specific resistance mechanisms are essential.
- Antibiotic de-escalation, guided by AST, should be implemented whenever feasible to optimize treatment and preserve antibiotic efficacy.
More Related Videos
11:35Replication of the Ordered, Nonredundant Library of Pseudomonas aeruginosa strain PA14 Transposon Insertion Mutants
Published on: May 4, 2018
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Gene Regulation in Microbial Communities: Quorum Sensing
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy